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Abstract
Aims Glucagon-like peptide 1 receptor agonists (GLP-1
RA) induce weight loss and reduction in adipose tissue, but
the effects of GLP-1 RA on the distribution of fat deposits
have been poorly investigated.
Methods In 25 patients with type 2 diabetes (16 females
and 9 males, mean age 63.5 ± 8.8 years), treated with
GLP-1 RA (exenatide, n. 12; liraglutide, n.13), both before
and 3 months after starting treatment, an abdominal ultr-
asonographic scan, with Doppler of renal arteries, and
echocardiography were performed. Subcutaneous fat width
(peri-umbilical and sub-xiphoid), deep fat deposits (pre-
aortic, peri-renal, and epicardial), and renal resistive index
(RI) were evaluated.
Results GLP-1 RA induced highly significant (p\ 0.001)
decrease in BMI and in fat thickness at all the assessed
sites, without differences between exenatide and liraglutide
treatment. A slight decrease in RI (p = 0.055) was also
found. The percent changes of fat thickness was different
between sites (p\ 0.025), and the changes in subcutaneous
deposits showed no significant correlation (p = 0.064)
with those of deep fat deposits.
Conclusions A short course of treatment with GLP-1 RA,
besidesweight loss, induces a redistribution of adipose tissue
deposits, possibly contributing to a better cardiovascular risk
profile in patients with type 2 diabetes mellitus.
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Introduction
Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are
recently introduced drugs for treatment of patients with type 2
diabetes mellitus. These analogues of the glucagon-like pep-
tide-1 (GLP-1) incretin stimulate glucose-dependent insulin
secretion induced by food ingestion and suppress inappro-
priately elevated glucagon secretion, thereby improving glu-
cose homeostasis. Moreover, they show a protective effect on
pancreatic beta cellmass. In addition, these drugs delaygastric
empting and reduce food intake, which in turn promotes a
progressive and sustainedweight loss. This loss results from a
reduction in fat mass rather than lean mass [1] which starts
shortly after the beginning of treatment with either exenatide
[2, 3] or liraglutide [1, 4]. According to a meta-analysis of
randomized controlled trials, the extent of weight decrease
averages 2.9 kg, with no significant difference between exe-
natide and liraglutide treatments [5].
Interestingly, a weight loss of such moderate entity
is not unimportant. It has been shown that significant
health benefits (blood pressure reduction, lipid profile
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improvement) can be achieved [6] even with modest
weight reduction. In addition, GLP-1 receptor agonists
induce a preferential decrease in visceral fat [7], which is
characterized by proinflammatory properties. Indeed, adi-
pose tissue is made up of distinct components with dif-
ferent metabolic activities, function, and health impact. For
instance, visceral fat levels seem to predict the risk of
cardiovascular disease better than crude anthropometric
indexes as BMI or waist circumference [8].
For this reason, it should be stressed how imaging studies
are highly valuable tools to investigate fat mass deposits
since they allow to study not only the entity, but also the
distribution of adipose tissue. It is well known that the most
accurate evaluation of fat tissue deposits at a particular site
is acquired through computed tomography (CT) and nuclear
magnetic resonance (NMR) techniques. Ultrasonography
(US) is also a valuable tool to explore several superficial
and deep sites of adipose tissue deposits. However, differ-
ently from CT and NMR, US is especially useful to inves-
tigate the changes of fat deposits over time [9] because it
does not imply radiation exposure is inexpensive, readily
available, rather accurate and reproducible. Through renal
Doppler US, it is also possible to assess the renal resistive
index (RI), a measurement of renal vascular resistance
which reflects systemic vascular involvement [10].
In this study, we have employed US to investigate the
short-term effects of incretin therapy on the extent and
distribution of adipose tissue deposits. Thus, we have
measured the changes in the fat thickness of several sub-
cutaneous and visceral fat deposits, as well as in the RI, in
a group of patients with type 2 diabetes mellitus treated for
3 months with either exenatide or liraglutide according to
the current Italian guidelines [11].
Materials and methods
We investigated 27 patients with type 2 diabetes mellitus,
consecutively recruited, who started assuming therapy with
GLP-1 receptor agonists, according to the current guide-
lines from Italian Public Health System Authority. All
patients gave their informed consent, and the study was
approved by the local ethics committee. All patients had
poor metabolic control of diabetes, despite being treated
with metformin at the maximal tolerated dose. One patient
discontinued exenatide treatment because of intestinal side
effects (nausea and vomiting), and another patient treated
with liraglutide was lost at follow-up. Thus, the final
investigated patient group included 25 subjects (16 females
and 9 males, mean age 63.5 ± 8.8 years), who were treated
subcutaneously either with exenatide (12 patients) or with
liraglutide (13 patients). Patients taking exenatide were
initially treated with 5.0 mcg twice daily for the first month
and with 10 mcg BID thereafter. Liraglutide therapy was
administered at the dose of 1.2 mg once a day.
Anthropometric parameters (BMI, waist circumference),
HbA1c, creatinine for the eGFR estimate through the
CKD-EPI equation [12], and lipid profile (including total,
HDL-, LDL-cholesterol and triglyceride levels) were
evaluated, before and after treatment, in all patients.
Moreover, in all subjects, fat thickness was measured by
US scans at several sites of peripheral and central fat
deposits, both before and 3 months after starting GLP-1
receptor agonists treatment. In more detail, subcutaneous
fat width was investigated with standard technique in the
peri-umbilical (peri-umbilical fat—PUF) and sub-xiphoid
(sub-xiphoid fat—SXF) region, whereas deep abdominal
fat deposits were determined by scanning the peri-renal
(peri-renal fat—PRF) and pre-aortic (pre-aortic fat—PAF)
regions by the same well-trained operator, who also mea-
sured the RI of renal arteries by Doppler US. Epicardial fat
(EpiF) thickness was measured by another specifically
experienced sonographer. Both operators were blinded to
the patients’ data. All the abdominal measurements were
made in the morning after an overnight fast by utilizing a
Esaote Technos ultrasound scanner. For the investigation
of subcutaneous fat pads, patients were asked to hold their
breath (in the mid-expiratory phase) while the probe just
touched the skin, to prevent compression. Through a lon-
gitudinal scan from the xiphoid process to the navel along
the linea alba, fat thickness was measured at 5 cm from the
umbilicus on the xiphoid–umbilical line and just below the
xiphoid process, utilizing a linear probe (8–12.5 MHz).
The probe was kept perpendicular to the skin of the upper
median abdomen, and almost parallel to the surface of the
liver with the convex probe (3.5–5 MHz). The peri-renal
and pre-aortic fat thickness was measured with a
3.5–5 MHz convex probe. For peri-renal fat, longitudinal
scanning was performed and the probe was slowly moved
laterally until the optimal position was found, at which the
surface of the kidney was almost parallel to the skin. Then,
the thickness of fat was measured from the inner side of the
abdominal musculature to the surface of the kidney, and
the average of both sides was defined as fat width at that
site. For pre-aortic fat thickness, in a transverse abdominal
scan just above the umbilicus level, the width of the layer
between the internal face of the abdominal muscle and the
anterior wall of the aorta was measured [13–15]. The RI
was calculated according to the formula RI = S-D/S,
where S is the height of the systolic peak and D is the
height of the end diastolic trough, as previously reported
[16]. Epicardial fat was assessed with standard technique
by a Esaote MyLab 30 instrument, equipped with a
2.5–3.5 MHz sectorial probe, on the free wall of right
ventricle from both parasternal long- and short-axis views,
and the average value was considered [17]. The within-
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operator variability demonstrated a very high repeatability
of the methods, as previously reported [18].
Statistical analysis
For all the parameters, the baseline values were compared
to those observed after 3 months of incretin therapy by
Wilcoxon’s signed-rank test for repeated measurements on
the same subject. A more robust standard t test for paired
samples was applied as well. The level of significance was
set at alpha = 0.05. Since the variance of the populations
was not known, a Fisher’s test for equality of variances was
performed prior to each t test and the estimate of the var-
iance population was chosen accordingly. The percent
changes were also compared by Wilcoxon’s test.
To determine similar patterns in the variation of fat
thickness among patients, a hierarchical clustering algo-
rithm based on ward’s minimum variance method, as an
exploratory technique, was employed. Such an analysis
provides a hierarchy of clusters of patients, who are
homogeneous inside each group for the considered vari-
ables (fat thickness changes). No structural variables such
as age and BMI have been used in the clustering.
A canonical correlation analysis between subcutaneous
and visceral fat variations was used to test if the overall
changes of deep adipose tissue deposits somehow corre-
lated with those of superficial fat stores.
Results
The mean serum HbA1c levels of the patient group
decreased from 9.5 ± 1.2 to 8.2 ± 1.3 % (from
80.5 ± 13.0 to 66.3 ± 14.2 mmol/mol) (p = 0.006) after
3 months of incretin therapy. Lipid profile did not show
significant variations (data not shown), except a decrease
in the triglyceride levels (from 191.9 ± 74.1 to
157.3 ± 45.6 mg/dL; p = 0.032).
The main results concerning anthropometric and fat
thickness variables are reported in Table 1 and Fig. 1. As
shown, the employed drugs, besides loss of weight, BMI
and waist circumference, induced a highly significant
decrease in fat thickness at all the assessed sites, although
the percent changes were not equal among different sites.
The percent changes of SXF, PRF, and EpiF were signifi-
cantly more marked than the percent changes of weight and
BMI, as well as than PUF and PAF (p\ 0.025 for all) (see
Fig. 1). Since no significant difference was found between
the 12 patients treated with exenatide and the 13 treated
with liraglutide, their data were pooled in the subsequent
analysis. A very slight decrease in renal RI (0.645 ± 0.030
vs. 0.642 ± 0.028, p = 0.055; D % = -0.4 ± 0.9 %) was
found, too, whereas no significant change during therapy
was found in either creatinine (Cr) (0.9 ± 0.3 vs.
0.9 ± 0.2 mg/dL; p = 0.686) or eGFR (79.1 ± 19.7 vs.
78.7 ± 19.1 mL/min/1.73 m2; p = 0.903) values. Both the
parametric and the nonparametric tests gave analogous
results.
The only variable showing gender-related difference in
behavior was Cr (p = 0.041 by Wilcoxon’s test). However,
the cluster analysis on fat thickness changes showed that a
subset of three patients had peculiar behavior, and after
further scrutiny, they were considered as outliers. By per-
forming again the tests for paired samples on the remaining
patients, we confirmed the results of previous analysis, but
Cr changes did not show significant difference between
sexes.
Finally, when we tested the correlation between treat-
ment-induced changes of the set of subcutaneous (PUF and
SXF) and deep (PRF, PAF, and EpiF) fat deposits by
canonical correlation analysis and Wilks’ Lambda test, we
found a value of 0.064, which implies that the changes of
superficial and deep adipose tissue stores were not signif-
icantly correlated.
Discussion
Our short-term results show that the weight loss induced by
GLP-1 receptor agonists reflects a significant decrease in
Table 1 Clinical and
ultrasonography parameters
* p by Wilcoxon’s Rank test
Basal 3 months p* D %
Body mass index (Kg/m2) 35.2 ± 4.8 33.7 ± 4.6 \0.001 -4.4 ± 3.1
Weight (Kg) 89.4 ± 12.4 85.9 ± 12.9 \0.001 -4,1 ± 3.1
Waist circumference (cm) 115.8 ± 11.4 113.2 ± 10.6 0.004 -2.1 ± 3.0
Fat thickness (mm)
Peri-umbilical 56.5 ± 12.3 54.4 ± 12.1 \0.001 -3.9 ± 1.6
Sub-xyphoideal 21.4 ± 8.6 12.6 ± 8.5 \0.001 -9.0 ± 9.6
Pre-aortic 61.0 ± 13.9 58.8 ± 13.6 \0.001 -3.6 ± 1.8
Peri-renal 15.2 ± 4.9 14.2 ± 4.7 \0.001 -8.4 ± 5.5
Epicardial 9.4 ± 1.6 8.0 ± 1. 9 0.003 -13.0 ± 23.2
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fat thickness at different sites and that such changes do not
homogeneously occur in different fat deposits throughout
the body. A marginal effect on the RI in renal Doppler US
was also found.
Also, in our sample of patients with type 2 diabetes
mellitus treated with add-on incretin therapy, the loss of
weight (and adipose tissue) occurred early after the
beginning of therapy, according to previous reports [3, 4].
Long-term studies showed that such weight loss is then
sustained, which could be a major breakthrough not only in
the treatment of type 2 diabetes, but also potentially in the
treatment of obesity [19–21].
Interestingly, US proved to be a valuable tool to monitor
treatment-induced changes of adipose tissue storage, being
radiation-free, low cost, widely diffused, and repeatable,
which suggests its wider use in the common clinical
practice [9, 14, 15]. In addition, since US may investigate
the width of adipose tissue pads at several body sites, such
a technique allowed us to investigate both subcutaneous
and visceral fat deposits. For this reason, since at our
knowledge no work has at present compared the effects of
this therapy on different fat deposits, we investigated
several storage sites indicated by previous literature reports
[13–15, 17].
The latter point is crucial, at the light of many recent
acquisitions on the so-called adipose organ. An increas-
ingly accepted concept is that the latter is not homogeneous
in terms of anatomy, metabolism, and physiological regu-
lation [22, 23]. Accordingly, BMI and even waist
circumference are increasingly regarded as rather gross and
crude measurements of total adiposity, which could not
adequately account for the morbidity and mortality risk
associated with excess adiposity [8]. Instead, the regional
distribution of fat stores appears to be more important than
total adiposity, to induce the metabolic and vascular
complications of obesity [17, 22–26]. Moreover, a recent
paper in different African ethnic groups showed that
abdominal fat distribution, as evaluated by US, accounted
for the differences in insulin resistance and b-cells function
[27].
In this view, our results are of particular interest since
they show that even a short course of GLP-1 receptor
agonist treatment results in a significant decrease not only
of weight and BMI, but also of both subcutaneous and
visceral fat deposits. The lack of significant difference
between exenatide and liraglutide action seems to confirm
that this is a ‘‘class’’ effect of these drugs [5]. Moreover,
the changes of fat thickness did not show substantial gen-
der-related differences. It should be particularly stressed
how different deep deposits of adipose tissue shrank shortly
after starting therapy, the decrease in certain fat pads being
particularly pronounced (see Fig. 1). Differently from the
changes of pre-aortic fat, particularly important, appear
those observed in peri-renal and epicardial fat thickness,
the percent change of which was much more marked than
that of waist circumference. The latter is a simpler but
crude predictor of cardiovascular risk, whose predictive
ability in serial measurements has been recently questioned
[28]. Our data emphasize how these deep fat deposits are
rapidly affected during incretin-related weight loss [29], as
after other interventions like diet [30] and exercise [31].
This let us hypothesize that the US technique could become
a sensitive indicator and a useful tool for follow-up studies
of the adiposopathic distribution of fat, the changes of
which could influence cardiovascular risk. For this impor-
tant reason, the implementation of carefully standardized
US measurement protocols is crucial to obtain accurate and
reliable results, particularly in longitudinal studies [32]. As
a fact, visceral adipose tissue (particularly epicardial fat)
seems to be metabolically more active and capable to
secrete a wider arrange of cytokines than subcutaneous fat
[33]. Looking at our results (see Fig. 1), and considering
the loose relationships among the changes in thickness of
subcutaneous and deep fat pads (and even among deep
storage sites), it is apparent as GLP-1 receptor agonists not
only decrease weight but also significantly influence fat
distribution. Interestingly, at the light of the accumulating
evidence on the beneficial cardiovascular effects of these
drugs [34], the assessment of some deep fat deposits seems
more predictive of increased cardiovascular risk, compared
with that of other sites. Also, oxygen consumption capacity
during exercise, which in turn reflects cardiorespiratory
Fig. 1 The box plots report the percent changes of body mass index
(BMI) and weight, faced to those of the fat thickness of different
subcutaneous (PUF peri-umbilical fat, and SXF sub-xiphoid fat) and
deep (PAF pre-aortic fat; PRF peri-renal fat; EpiF epicardial fat)
adipose tissue deposits, following 3 months of therapy with GLP-1
receptor agonists. *p B 0.02 versus BMI, weight, PUF, PAF
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fitness, appears to be associated to intra-abdominal fat
accumulation in patients with type 2 diabetes [35]. Our
finding of a slight and marginally significant reduction in
the renal RI, with unchanged eGFR, should also be worth
to be mentioned, since this index of renal vascular resis-
tance was reported to be higher in patients with diabetes
[10, 16].
In conclusion, our data demonstrated that even a short
course of treatment with GLP-1 receptor agonists, besides
weight loss, induces a redistribution of adipose tissue
deposits, possibly contributing to a better cardiovascular
risk profile, in patients with type 2 diabetes mellitus.
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